Literature DB >> 32324852

The independent reduction in mortality associated with guideline-directed medical therapy in patients with coronary artery disease and heart failure with reduced ejection fraction.

Natasha K Wolfe1, Joshua D Mitchell1, David L Brown1.   

Abstract

AIMS: Guideline-directed medical therapy (GDMT) is underutilized in patients with coronary artery disease (CAD). However, there are no studies evaluating the impact of GDMT adherence on mortality among patients with CAD and heart failure with reduced ejection fraction (HFrEF). We sought to investigate the association of GDMT adherence with long-term mortality in patients with CAD and HFrEF. METHODS AND
RESULTS: Surgical Treatment for Ischaemic Heart Failure (STICH) was a trial of patients with an left ventricular ejection fraction ≤35% and CAD amenable to coronary artery bypass graft surgery (CABG) who were randomized to CABG plus medical therapy (N = 610) or medical therapy alone (N = 602). Median follow-up time was 9.8 years. We defined GDMT for the treatment of CAD and HFrEF as the combination of at least one antiplatelet drug, a statin, a beta-blocker, and an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker. The primary outcome was all-cause mortality. Assessment of the independent association between GDMT and mortality was performed using multivariable Cox regression with GDMT as a time-dependent covariate. In the CABG arm, 63.6% of patients were on GDMT throughout the study period compared to 66.5% of patients in the medical therapy arm (P = 0.3). GDMT was independently associated with a significant reduction in mortality (hazard ratio 0.65, 95% confidence interval 0.56-0.76; P < 0.001).
CONCLUSION: GDMT is associated with reduced mortality in patients with CAD and HFrEF independent of revascularization with CABG. Strategies to improve GDMT adherence in this population are needed to maximize survival. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author(s) 2020. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Cardiomyopathy; Coronary artery disease; Heart failure; Outcome

Mesh:

Substances:

Year:  2021        PMID: 32324852      PMCID: PMC8294676          DOI: 10.1093/ehjqcco/qcaa032

Source DB:  PubMed          Journal:  Eur Heart J Qual Care Clin Outcomes        ISSN: 2058-1742


  22 in total

Review 1.  Self-report measures of medication adherence behavior: recommendations on optimal use.

Authors:  Michael J Stirratt; Jacqueline Dunbar-Jacob; Heidi M Crane; Jane M Simoni; Susan Czajkowski; Marisa E Hilliard; James E Aikens; Christine M Hunter; Dawn I Velligan; Kristen Huntley; Gbenga Ogedegbe; Cynthia S Rand; Eleanor Schron; Wendy J Nilsen
Journal:  Transl Behav Med       Date:  2015-07-09       Impact factor: 3.046

2.  Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease.

Authors:  L Kristin Newby; Nancy M Allen LaPointe; Anita Y Chen; Judith M Kramer; Bradley G Hammill; Elizabeth R DeLong; Lawrence H Muhlbaier; Robert M Califf
Journal:  Circulation       Date:  2006-01-09       Impact factor: 29.690

3.  Cost-effectiveness of providing full drug coverage to increase medication adherence in post-myocardial infarction Medicare beneficiaries.

Authors:  Niteesh K Choudhry; Amanda R Patrick; Elliott M Antman; Jerry Avorn; William H Shrank
Journal:  Circulation       Date:  2008-02-19       Impact factor: 29.690

4.  2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes.

Authors:  Juhani Knuuti; William Wijns; Antti Saraste; Davide Capodanno; Emanuele Barbato; Christian Funck-Brentano; Eva Prescott; Robert F Storey; Christi Deaton; Thomas Cuisset; Stefan Agewall; Kenneth Dickstein; Thor Edvardsen; Javier Escaned; Bernard J Gersh; Pavel Svitil; Martine Gilard; David Hasdai; Robert Hatala; Felix Mahfoud; Josep Masip; Claudio Muneretto; Marco Valgimigli; Stephan Achenbach; Jeroen J Bax
Journal:  Eur Heart J       Date:  2020-01-14       Impact factor: 29.983

5.  Patterns and intensity of medical therapy in patients undergoing percutaneous coronary intervention.

Authors:  William B Borden; Rita F Redberg; Alvin I Mushlin; David Dai; Lisa A Kaltenbach; John A Spertus
Journal:  JAMA       Date:  2011-05-11       Impact factor: 56.272

6.  Treatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costs.

Authors:  Edmond L Toy; Nicolas U Beaulieu; Joshua M McHale; Timothy R Welland; Craig A Plauschinat; Andrine Swensen; Mei Sheng Duh
Journal:  Respir Med       Date:  2010-09-29       Impact factor: 3.415

7.  Optimal medical therapy with or without PCI for stable coronary disease.

Authors:  William E Boden; Robert A O'Rourke; Koon K Teo; Pamela M Hartigan; David J Maron; William J Kostuk; Merril Knudtson; Marcin Dada; Paul Casperson; Crystal L Harris; Bernard R Chaitman; Leslee Shaw; Gilbert Gosselin; Shah Nawaz; Lawrence M Title; Gerald Gau; Alvin S Blaustein; David C Booth; Eric R Bates; John A Spertus; Daniel S Berman; G B John Mancini; William S Weintraub
Journal:  N Engl J Med       Date:  2007-03-26       Impact factor: 91.245

8.  Optimal medical therapy improves clinical outcomes in patients undergoing revascularization with percutaneous coronary intervention or coronary artery bypass grafting: insights from the Synergy Between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery (SYNTAX) trial at the 5-year follow-up.

Authors:  Javaid Iqbal; Yao-Jun Zhang; David R Holmes; Marie-Claude Morice; Michael J Mack; Arie Pieter Kappetein; Ted Feldman; Elizabeth Stahle; Javier Escaned; Adrian P Banning; Julian P Gunn; Antonio Colombo; Ewout W Steyerberg; Friedrich W Mohr; Patrick W Serruys
Journal:  Circulation       Date:  2015-02-24       Impact factor: 29.690

9.  Initial Invasive or Conservative Strategy for Stable Coronary Disease.

Authors:  David J Maron; Judith S Hochman; Harmony R Reynolds; Sripal Bangalore; Sean M O'Brien; William E Boden; Bernard R Chaitman; Roxy Senior; Jose López-Sendón; Karen P Alexander; Renato D Lopes; Leslee J Shaw; Jeffrey S Berger; Jonathan D Newman; Mandeep S Sidhu; Shaun G Goodman; Witold Ruzyllo; Gilbert Gosselin; Aldo P Maggioni; Harvey D White; Balram Bhargava; James K Min; G B John Mancini; Daniel S Berman; Michael H Picard; Raymond Y Kwong; Ziad A Ali; Daniel B Mark; John A Spertus; Mangalath N Krishnan; Ahmed Elghamaz; Nagaraja Moorthy; Whady A Hueb; Marcin Demkow; Kreton Mavromatis; Olga Bockeria; Jesus Peteiro; Todd D Miller; Hanna Szwed; Rolf Doerr; Matyas Keltai; Joseph B Selvanayagam; P Gabriel Steg; Claes Held; Shun Kohsaka; Stavroula Mavromichalis; Ruth Kirby; Neal O Jeffries; Frank E Harrell; Frank W Rockhold; Samuel Broderick; T Bruce Ferguson; David O Williams; Robert A Harrington; Gregg W Stone; Yves Rosenberg
Journal:  N Engl J Med       Date:  2020-03-30       Impact factor: 91.245

10.  Atherosclerosis secondary prevention performance measures after coronary bypass graft surgery compared with percutaneous catheter intervention and nonintervention patients in the Get With the Guidelines database.

Authors:  Loren F Hiratzka; Kim A Eagle; Li Liang; Gregg C Fonarow; Kenneth A LaBresh; Eric D Peterson
Journal:  Circulation       Date:  2007-09-11       Impact factor: 29.690

View more
  1 in total

1.  Guideline-directed medical therapy in heart failure patients with reduced ejection fraction in Oman: utilization, reasons behind non-prescribing, and dose optimization.

Authors:  Safiya Al-Aghbari; Juhaina Salim Al-Maqbali; Abdullah M Al Alawi; Mohammed Al Za'abi; Ibrahim Al-Zakwani
Journal:  Pharm Pract (Granada)       Date:  2022-04-13
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.